Jump to content

Review queue: Difference between revisions

From IdeaWazaWiki
Add Why the metformin aging trial struggled for money to review queue
Restore Review queue content and add Why the metformin aging trial struggled for money
Line 1: Line 1:
= Why the First Trial Designed to Treat Aging Itself Has Waited Years for a Funder =
Recently added and updated articles on this wiki, newest first. See [[New]] for the main list of new pages.


''This page is educational and is not medical advice. It is not advice to start, stop, or change any medication.''
== To review ==
* [[Why the metformin aging trial struggled for money]] (November 21)
* [[Private digital cash and who runs the mint]] (November 21)
* [[Electronics engineering]] (November 20)
* [[Time credits for elder care and help without shame]] (November 20)
* [[Maori speech recognition and community-owned data]] (November 20)
* [[Crisis hotlines that refuse nonconsensual rescue]] (November 19)
* [[Medical drones and the end of hoarded supplies]] (November 19)
* [[Old blood versus young blood in aging research]] (November 18)
* [[Reading the sealed Herculaneum scrolls with AI]] (November 18)
* [[Geel family care and help without coercion]] (November 17)
* [[Reproducible builds and trust in free software]] (November 17)
* [[Why WHO dropped old age as a diagnosis]] (November 16)
* [[Growing food in Moon dust starts with soil]] (November 16)
* [[Why BitTorrent alone cannot replace Hugging Face or GitHub]] (November 15)
* [[ForgeFed and federated code forges]] (November 15)
* [[Hosting a full web app on ICP canisters]] (November 15)
* [[Hosting a full web app on Arweave with AO as the backend]] (November 15)
* [[ICP versus Arweave and AO for decentralized platforms]] (November 15)
* [[Distributing AI model weights with BitTorrent and content addressing]] (November 15)
* [[Making decentralized nodes easy and worth running]] (November 15)
* [[A plan for a decentralized Hugging Face and GitHub]] (November 15)
* [[Unconditional cash for people without homes]] (November 15)
* [[Snowflake volunteer proxies against censorship]] (November 15)
* [[Next-token prediction and cross-entropy loss]] (November 14)
* [[Attention in transformers explained with numbers]] (November 14)
* [[Token embeddings and the geometry of meaning]] (November 14)
* [[How central gradient descent is to modern AI]] (November 14)
* [[Urban cable cars for hillside neighborhoods]] (November 14)
* [[Retracted science and AI research assistants]] (November 14)
* [[Precision fermentation and the insulin precedent]] (November 13)
* [[Off-grid mesh texting when cell towers go dark]] (November 13)
* [[Why village cash transfers barely raised prices]] (November 12)
* [[The ovary as a fast test for aging drugs]] (November 12)
* [[Factories in orbit and what they bring back to Earth]] (November 11)
* [[Offline captions for deaf and hard of hearing people]] (November 11)
* [[Salt-tolerant crops for land written off as ruined]] (November 10)
* [[Why read-only Wikipedia mirrors are not enough]] (November 10)
* [[Robotaxis and freedom for people who cannot drive]] (November 9)
* [[Registered reports and peer review before results]] (November 9)
* [[Community land trusts and lasting home affordability]] (November 8)
* [[Why abolishing the insanity defense is not enough]] (November 8)
* [[Harvesting drinking water from desert air]] (November 7)
* [[Aging clocks and faster longevity trials]] (November 7)
* [[Reusable rockets and the collapse of launch prices]] (November 6)
* [[Proof of personhood without biometric dossiers]] (November 6)
* [[Court-ordered outpatient psychiatry and the evidence]] (November 5)
* [[Gene drives against malaria and who decides]] (November 5)
* [[Adversarial collaboration between rival scientists]] (November 4)
* [[Cultivated meat bans and food abundance]] (November 4)
* [[Growing houses from fungi on the Moon and Mars]] (November 3)
* [[Nostr and social identity no platform can ban]] (November 3)
* [[Cargo airships for places without roads]] (November 2)
* [[Savings circles for people who cannot save alone]] (November 2)
* [[Onshoring manufacturing with robots and AI]] (November 1)
* [[Why the Rosenhan study failed critics of psychiatry]] (November 1)
* [[Pig organs and the end of organ scarcity]] (November 1)
* [[Sneakernets and USB drives against censorship]] (October 31)
* [[Prediction markets for scientific replication]] (October 31)
* [[Perennial grains and the end of yearly replanting]] (October 30)
* [[E-bikes and the path to transport abundance]] (October 30)
* [[Hearing voices groups as an alternative to diagnosis]] (October 29)
* [[Giving cash to people without homes]] (October 29)
* [[Self-healing concrete and lessons from Rome]] (October 28)
* [[Dog aging trials as a shortcut for human longevity]] (October 28)
* [[Offline AI tutors for places without internet]] (October 27)
* [[How Arweave prices storage for 200 years]] (October 27)
* [[Lunar lava tubes as the first Moon homes]] (October 26)
* [[Uranium from seawater and nuclear fuel abundance]] (October 26)
* [[Space-based solar power and its first real markets]] (October 25)
* [[Soteria houses]] (October 25)
* [[How Israel ended its water shortage]] (October 25)
* [[Lithium from oilfield brine and battery abundance]] (October 25)
* [[Why more people do not join projects with a massive transformative purpose]] (October 24)
* [[3D-printed houses and the path to housing abundance]] (October 24)
* [[Animals that barely age and the fight against aging]] (October 24)
* [[How to keep public data portals current]] (October 24)
* [[Why municipal open data portals go stale]] (October 23)
* [[Geothermal drilling and the path to energy abundance]] (October 23)
* [[Self-replicating machines and the path to abundance]] (October 23)
* [[Urban mining and why e-waste is richer than ore]] (October 22)
* [[Why vertical farms fail and what food abundance needs]] (October 22)
* [[Lab-grown diamond in manufacturing, computing, and medicine]] (October 21)
* [[Asteroid mining and why water comes first]] (October 21)
* [[Backing up civilization from seed vaults to the Moon]] (October 20)
* [[Hospital price transparency files and lower bills]] (October 20)
* [[Why tool libraries fail and what makes them last]] (October 20)
* [[Debanking and the case for censorship-resistant money]] (October 20)
* [[Occupational licensing as artificial scarcity]] (October 20)
* [[Supported decision-making as an alternative to coercion]] (October 19)
* [[Time prices and measuring abundance]] (October 19)
* [[Desalination and the path to water abundance]] (October 19)
* [[Sovereign AI agents and prompt injection]] (October 19)
* [[Microbial protein and the path to food abundance]] (October 19)
* [[Benefits cliffs as a scarcity trap for workers]] (October 18)
* [[Link rot and the scarcity of reliable knowledge]] (October 18)
* [[Psychiatric coercion and the human rights gap]] (October 17)
* [[Right to repair as a path to durable abundance]] (October 17)
* [[Community mesh networks as freedom infrastructure]] (October 16)
* [[Retrieval-augmented generation]] (October 16)
* [[Why GrapheneOS matters for freedom technology]] (October 16)
* [[Local-first software and data ownership]] (October 16)
* [[Classifying aging as a treatable condition]] (October 16)
* [[Energy costs and the path to abundance]] (October 16)
* [[Using Godot to build non-game apps]] (October 16)
* [[Model Context Protocol]] (October 16)
* [[Portable reputation for agents]] (October 16)
* [[Running AI models locally]] (October 15)
* [[Why housing and care prices rise while goods prices fall]] (October 15)
* [[DDoS protection]] (October 15)
* [[Open-source software that should exist]] (October 15)
* [[Credit union small-dollar loans]] (October 15)
* [[A design for a permanent decentralized wiki using Arweave and Bitcoin Cash Memo]] (October 15)
* [[Stock options trading basics]] (October 15)
* [[How to evaluate claims about anti-aging treatments]] (October 14)
* [[Decentralized self-serve advertising]] (October 14)
* [[A design for decentralized, censorship-resistant advertising]] (October 14)
* [[How a DAO works]] (October 14)
* [[Spaced repetition]] (October 14)
* [[The cryptoeconomics of agent-to-agent commerce]] (October 14)
* [[Cryptocurrencies and wallets for AI agents using the x402 protocol]] (October 14)
* [[Low-fee, censorship-resistant cryptocurrencies]] (October 14)
* [[Self-custody of Bitcoin Cash for beginners]] (October 14)
* [[How to write a psychiatric advance directive]] (October 14)
* [[Installing GrapheneOS on a Pixel phone]] (October 14)
* [[The economics of extending healthy lifespan]] (October 14)
* [[Basic income through credit unions]] (October 13)
* [[Emergency fund planning]] (October 13)


The '''TAME trial''' (Targeting Aging with Metformin) is a planned study that asks whether one low cost, decades old diabetes pill can delay several diseases of old age at once. The science question is open, but the reason the trial has waited so long is mostly economic. Metformin is off patent and costs very little per dose, so no company can recover the cost of a large trial, and regulators have no approved use called aging for anyone to sell into.<ref name="npr2024" /><ref name="innovita2026" /> The scarce input is a funder willing to pay for knowledge that, once produced, belongs to everyone. Solving that problem is a step from scarcity toward abundance: a pill that already exists in huge supply would become tested knowledge that any health system on Earth could use, and the same template could open the door to better drugs that target [[Aging|aging]] itself.
== See also ==
* [[Proposed pages]]
* [[Areas of research and study to develop]]
* [[New]]
* [[Page ideas]]


==What the trial is meant to test==
[[Category:Hubs]]
The trial was designed by gerontologists brought together with support from a National Institute on Aging grant, and it received planning funding from the American Federation for Aging Research (AFAR), a nonprofit.<ref name="cell2016" /> In a 2016 paper in ''Cell Metabolism'', the lead designers explained why metformin was chosen. It has more than 60 years of use, a strong safety record, and earlier trials and observational studies linking it to lower rates of several age related diseases.<ref name="cell2016" />
[[Category:Wiki maintenance]]
 
The plan is to enroll 3,000 people aged 65 to 79 at about 14 centers in the United States and follow them for six years, with half taking metformin and half taking a placebo.<ref name="cell2016" /><ref name="npr2024" /><ref name="afar" /> The authors stated the purpose plainly: TAME is meant to create a model for testing drugs that delay aging, so that later and better drugs have a path to follow.<ref name="cell2016" />
 
==The 2015 FDA meeting and the composite endpoint==
The Food and Drug Administration (FDA) approves drugs for specific diseases, and it does not treat aging as one.<ref name="afar" /> In June 2015, ''Nature'' reported that researchers were asking regulators to consider aging a treatable condition.<ref name="nature2015" /> In a 2024 NPR report, one of the scientists involved recalled that a group of researchers went to the FDA that year to ask for a metformin trial aimed at delaying a variety of diseases, and that the agency was receptive.<ref name="npr2024" />
 
The design that came out of this work avoids asking the FDA to accept aging as a disease. Instead of measuring aging directly, TAME measures the time until a person develops any one of a cluster of conditions: cardiovascular events, cancer, dementia, or death.<ref name="cell2016" /> If one pill delays the whole cluster, that is evidence it acts on something those diseases share, which is the biology of aging. A 2025 Science|Business report described the FDA's willingness to allow a trial built around protection against any of several age related diseases, rather than a single disease, as a significant step.<ref name="sb2025" /> Related questions about how regulators label and code aging are covered on [[Classifying aging as a treatable condition|Classifying aging as a treatable condition]] and [[Why WHO dropped old age as a diagnosis|Why WHO dropped old age as a diagnosis]].
 
==Why the money never arrived==
NPR reported in 2024 that the trial was estimated to cost between 45 and 70 million dollars, and that the National Institutes of Health had set aside about 5 million dollars, which was not enough.<ref name="npr2024" /> The trial's lead fundraiser told NPR that the main obstacle was that metformin is a generic drug, so no pharmaceutical company stood to make money from it, and that the effort had turned to philanthropists and foundations.<ref name="npr2024" />
 
In a 2025 Science|Business interview, the same researcher said a billionaire had first been set to fund the trial and then lost his money. A private foundation later agreed to fund only a third of the trial, leaving the team to seek the other two thirds, at an estimated 8 million dollars a year for four to five years. He warned that without more money the trial might have to enroll fewer people.<ref name="sb2025" />
 
A September 2026 review of the trial's history reported that, as of mid 2026, TAME was still awaiting funding and had not enrolled a single participant.<ref name="innovita2026" /> In an August 2025 interview, the lead researcher said the trial was "now being handled within ARPA-H," the federal Advanced Research Projects Agency for Health, and that he could not give a full update.<ref name="lifespan2025" /> In March 2026, ARPA-H did fund a different aging trial: up to 38 million dollars for VITAL-H, which will test rapamycin, dapagliflozin, and semaglutide against placebo in 726 adults in their 60s.<ref name="uth2026" /> Metformin is not one of its arms.
 
==An orphan problem, not a metformin problem==
TAME is one case of a wider pattern. A 2021 study in the journal ''Trials'' found that drug companies are rarely willing to invest in new uses of approved medicines once patent or regulatory protection has ended, which makes these medicines "financial orphans."<ref name="trials2021" /> As a result, new uses for old drugs are mostly studied in independent trials run by universities and research groups, and those groups often cannot pay for the large late stage trials needed to confirm early results.<ref name="trials2021" />
 
The irony is that the features that make metformin a good public health candidate are the same features that make it a poor commercial one. If the trial succeeded, its lead fundraiser said, many people could use the drug at once, and it would be something everybody could afford.<ref name="npr2024" /> Low price is a benefit to patients and a barrier to sponsors. Questions about who carries the costs and gains of longer lives are explored further on [[Who pays for a longer life|Who pays for a longer life]].
 
==Ways to fund public good trials==
The ''Trials'' study reviewed several ways to fund research on off patent drugs.<ref name="trials2021" />
 
* '''Government and philanthropic grants''' are the familiar route and are widely used, but they have so far fallen short for TAME.<ref name="trials2021" /><ref name="npr2024" />
* '''Crowdfunding''' can support small early projects, but the stakeholders interviewed agreed that large clinical trials are too expensive to fund this way.<ref name="trials2021" />
* '''Public private partnerships''' join public bodies and companies around a shared goal, such as access to medicines.<ref name="trials2021" />
* '''Social impact bonds''', also called pay for success, let private investors fund a trial, with an outcome payer such as a government or insurer repaying them with a return only if an agreed outcome is reached. Interviewees saw promise but also high transaction costs and difficulty in measuring health outcomes.<ref name="trials2021" />
* '''Agency style programs''' such as ARPA-H can fund trials directly, as the VITAL-H contract shows.<ref name="uth2026" />
 
Some researchers argue the sums involved are small for large public funders. One scientist quoted by Science|Business estimated that funding major trials to establish reliable aging biomarkers would cost on the order of 70 to 100 million dollars, which he called "a drop in the ocean" for the NIH or EU budgets.<ref name="sb2025" /> Faster measures of aging could also shorten future trials, a theme covered on [[Aging clocks and faster longevity trials|Aging clocks and faster longevity trials]].
 
==Honest limits==
The case for funding TAME is a case for getting an answer, not a promise that the answer will be yes. Metformin may not slow aging in healthy older people.
 
* Most of the human evidence is observational. Supporters themselves say it shows associations in people with diabetes and stops short of proving cause and effect.<ref name="npr2024" />
* A 2022 Danish registry study found that people with type 2 diabetes starting metformin had higher mortality than matched people without diabetes, including in twin pairs, which challenged an earlier finding of a survival advantage.<ref name="keys2022" />
* The MILES study, a small crossover trial of 14 people around age 70, found that six weeks of metformin changed the activity of hundreds of genes in muscle and fat tissue, including pathways linked to aging. This suggests biological effects but does not show longer or healthier lives.<ref name="miles2018" />
* A 2019 randomized trial of 53 older adults found that metformin blunted some benefits of 12 weeks of aerobic exercise, including gains in insulin sensitivity and muscle mitochondrial respiration. The authors said more studies are needed before prescribing metformin to slow aging.<ref name="konopka2019" />
* While TAME waited, the field moved on. Newer trials such as VITAL-H test other drugs, some of which have commercial futures, so metformin may never be the first aging drug tested at scale.<ref name="innovita2026" /><ref name="uth2026" />
 
None of this weakens the funding argument. A large, well run trial is the way to settle these disputes, and a clear negative result would also be public knowledge worth having. Prespecified designs and open reporting, discussed on [[Registered reports and peer review before results|Registered reports and peer review before results]], help make either outcome trustworthy.
 
==Discussion questions, essay ideas, and learning related AI prompt ideas==
* Explain why a generic drug that costs very little per dose can be harder to test than an expensive new drug, and what that reveals about how medical knowledge is produced.
* Compare grants, social impact bonds, public private partnerships, and agency programs like ARPA-H as ways to pay for a trial of an off patent drug, and judge which fits a six year aging trial best.
* Describe how a composite endpoint of several age related diseases lets researchers test aging without asking regulators to call aging a disease, and weigh the strengths and weaknesses of that design.
* Argue whether a clear negative result from a large aging trial would be worth its cost as public knowledge, and explain who would benefit from it.
* Outline a funding plan that could raise the remaining money for a public good trial within two years, naming the kinds of funders involved and the risks each would carry.
* Assess what the mixed evidence on metformin, including the exercise findings, means for how society should choose which candidate drugs get tested first.
 
==See also==
* [[Aging|Aging]]
* [[Classifying aging as a treatable condition|Classifying aging as treatable]]
* [[Aging clocks and faster longevity trials|Aging clocks and faster trials]]
* [[Why WHO dropped old age as a diagnosis|WHO and old age as a diagnosis]]
* [[Old blood versus young blood in aging research|Old blood versus young blood]]
* [[The ovary as a fast test for aging drugs|Ovary as a test for aging drugs]]
* [[Who pays for a longer life|Who pays for a longer life]]
* [[Registered reports and peer review before results|Registered reports]]
* [[Abolishing aging|Abolishing aging]]
 
==References==
<references>
<ref name="cell2016">[https://pmc.ncbi.nlm.nih.gov/articles/PMC5943638/ Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. "Metformin as a Tool to Target Aging." Cell Metabolism, 2016.]</ref>
<ref name="afar">[https://www.afar.org/news/afar-initiative-in-the-news-npr-spotlights-tame-trial-and-afar-scientific-leadership American Federation for Aging Research. "AFAR Initiative in the News: NPR spotlights TAME Trial and AFAR Scientific Leadership." 2024.]</ref>
<ref name="nature2015">[https://www.nature.com/articles/522265a Check Hayden E. "Anti-ageing pill pushed as bona fide drug." Nature 522, 265 to 266, 17 June 2015.]</ref>
<ref name="npr2024">[https://www.npr.org/transcripts/1245872510 Aubrey A. NPR Morning Edition report and transcript on the TAME trial, 22 April 2024.]</ref>
<ref name="sb2025">[https://sciencebusiness.net/news/drug-development/anti-ageing-therapies-have-we-got-health-research-funding-wrong Matthews D. "Anti-ageing therapies: have we got health research funding wrong?" Science|Business, 7 August 2025.]</ref>
<ref name="innovita2026">[https://www.innovitaresearch.com/2026/09/26/tame-the-aging-trial-with-metformin-that-never-enrolled-a-patient/ Innovita Research. "TAME: The Aging Trial with Metformin That Never Enrolled a Patient." 26 September 2026.]</ref>
<ref name="lifespan2025">[https://lifespan.io/nir-barzilai-positive-evidence-for-metformin-is-mounting/ Mazin A. Interview on metformin and the TAME trial. Lifespan.io, 12 August 2025.]</ref>
<ref name="uth2026">[https://news.uthscsa.edu/ut-san-antonio-to-lead-38-million-national-trial-testing-drugs-to-extend-healthspan/ UT Health San Antonio. "UT San Antonio to lead 38 million dollar national trial testing drugs to extend healthspan." 4 March 2026.]</ref>
<ref name="trials2021">[https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05273-x Verbaanderd C, Rooman I, Huys I. "Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research." Trials, 2021.]</ref>
<ref name="keys2022">[https://pubmed.ncbi.nlm.nih.gov/36287641/ Keys MT et al. "Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study." International Journal of Epidemiology, 2022.]</ref>
<ref name="miles2018">[https://pubmed.ncbi.nlm.nih.gov/29383869/ Kulkarni AS et al. "Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults." Aging Cell, 2018.]</ref>
<ref name="konopka2019">[https://pubmed.ncbi.nlm.nih.gov/30548390/ Konopka AR et al. "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell, 2019.]</ref>
</references>
 
<!-- Last checked: November 2026 -->
 
[[Category:Aging]]
[[Category:Life extension]]
[[Category:Health]]
[[Category:Research]]

Revision as of 21:39, 21 November 2026

Recently added and updated articles on this wiki, newest first. See New for the main list of new pages.

To review

See also